Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 798

1.

Efficacy of Combined Cox-Maze IV and Ventricular Septal Myectomy for Treatment of Atrial Fibrillation in Patients With Obstructive Hypertrophic Cardiomyopathy.

Boll G, Rowin EJ, Maron BJ, Wang W, Rastegar H, Maron MS.

Am J Cardiol. 2019 Oct 11. pii: S0002-9149(19)31098-7. doi: 10.1016/j.amjcard.2019.09.029. [Epub ahead of print]

PMID:
31727261
2.

The ESC Risk Score is Less Reliable than ACC/AHA Risk Factors in Hypertrophic Cardiomyopathy: When Sensitivity Trumps Specificity.

Maron MS, Rowin EJ, Maron BJ.

Can J Cardiol. 2019 Jun 24. pii: S0828-282X(19)30434-9. doi: 10.1016/j.cjca.2019.06.018. [Epub ahead of print] No abstract available.

PMID:
31703825
3.

Coexistence of acute takotsubo syndrome and acute coronary syndrome.

Sharkey SW, Kalra A, Henry TD, Smith TD, Pink VR, Lesser JR, Garberich RF, Maron MS, Maron BJ.

Catheter Cardiovasc Interv. 2019 Nov 6. doi: 10.1002/ccd.28595. [Epub ahead of print]

PMID:
31696663
4.

Impact of Sex on Clinical Course and Survival in the Contemporary Treatment Era for Hypertrophic Cardiomyopathy.

Rowin EJ, Maron MS, Wells S, Patel PP, Koethe BC, Maron BJ.

J Am Heart Assoc. 2019 Nov 5;8(21):e012041. doi: 10.1161/JAHA.119.012041. Epub 2019 Oct 30.

5.

The Guidant Affair revisited…but this time with good news.

Maron BJ, Harris KM, Maron MS.

Heart Rhythm. 2019 Oct 5. pii: S1547-5271(19)30916-6. doi: 10.1016/j.hrthm.2019.10.010. [Epub ahead of print] No abstract available.

PMID:
31593780
6.

Increasing evidence that risk scores underperform in predicting sudden death in hypertrophic cardiomyopathy.

Maron M, Rowin E, Maron BJ.

Heart. 2019 Dec;105(24):1850-1851. doi: 10.1136/heartjnl-2019-315694. Epub 2019 Sep 24. No abstract available.

PMID:
31551293
7.

Defining Commotio Cordis.

Maron BJ, Sheppard CS.

Am J Cardiol. 2019 Nov 15;124(10):1649-1650. doi: 10.1016/j.amjcard.2019.08.006. Epub 2019 Aug 21. No abstract available.

PMID:
31537298
8.

Paradigm of Sudden Death Prevention in Hypertrophic Cardiomyopathy.

Maron BJ, Rowin EJ, Maron MS.

Circ Res. 2019 Aug 2;125(4):370-378. doi: 10.1161/CIRCRESAHA.119.315159. Epub 2019 Aug 1.

PMID:
31518168
9.

Guideline-Based Referral for Septal Reduction Therapy in Obstructive Hypertrophic Cardiomyopathy Is Associated With Excellent Clinical Outcomes.

Kimmelstiel C, Zisa DC, Kuttab JS, Wells S, Udelson JE, Wessler BS, Rastegar H, Kapur NK, Weintraub AR, Maron BJ, Maron MS, Rowin EJ.

Circ Cardiovasc Interv. 2019 Jul;12(7):e007673. doi: 10.1161/CIRCINTERVENTIONS.118.007673. Epub 2019 Jul 12.

PMID:
31296080
10.
11.

A Lethal Blow to the Chest as an Underdiagnosed Cause of Sudden Death in United Kingdom Sports (Football, Cricket, Rugby).

Cooper S, Woodford NW, Maron BJ, Harris KM, Sheppard MN.

Am J Cardiol. 2019 Sep 1;124(5):808-811. doi: 10.1016/j.amjcard.2019.05.050. Epub 2019 Jun 7.

PMID:
31277792
12.

Structurally Normal Hearts Are Uncommonly Associated With Sudden Deaths in Athletes and Young People.

Thiene G, Rizzo S, Schiavon M, Maron MS, Zorzi A, Corrado D, Maron BJ, Basso C.

J Am Coll Cardiol. 2019 Jun 18;73(23):3031-3032. doi: 10.1016/j.jacc.2019.03.497. No abstract available.

PMID:
31196462
13.

Chronic Heart Failure Is Infrequently Associated With Renal Dysfunction in Hypertrophic Cardiomyopathy.

Rowin EJ, Romashko M, Testani JM, Koethe BC, Saxena D, Udelson JE, Maron BJ, Maron MS.

J Card Fail. 2019 Aug;25(8):690-692. doi: 10.1016/j.cardfail.2019.05.012. Epub 2019 May 31. No abstract available.

PMID:
31158468
14.

Enhanced American College of Cardiology/American Heart Association Strategy for Prevention of Sudden Cardiac Death in High-Risk Patients With Hypertrophic Cardiomyopathy.

Maron MS, Rowin EJ, Wessler BS, Mooney PJ, Fatima A, Patel P, Koethe BC, Romashko M, Link MS, Maron BJ.

JAMA Cardiol. 2019 Jul 1;4(7):644-657. doi: 10.1001/jamacardio.2019.1391.

PMID:
31116360
15.

Impact of Effective Management Strategies on Patients With the Most Extreme Phenotypic Expression of Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Romashko M, Wang W, Rastegar H, Link MS, Maron MS.

Am J Cardiol. 2019 Jul 1;124(1):113-121. doi: 10.1016/j.amjcard.2019.04.002. Epub 2019 Apr 9.

PMID:
31027655
16.

Moving Beyond the Sarcomere to Explain Heterogeneity in Hypertrophic Cardiomyopathy: JACC Review Topic of the Week.

Maron BJ, Maron MS, Maron BA, Loscalzo J.

J Am Coll Cardiol. 2019 Apr 23;73(15):1978-1986. doi: 10.1016/j.jacc.2019.01.061. Review.

PMID:
31000001
17.

Safety, Side Effects and Relative Efficacy of Medications for Rhythm Control of Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Miller CAS, Maron MS, Estes NAM III,, Price LL, Rowin EJ, Maron BJ, Link MS.

Am J Cardiol. 2019 Jun 1;123(11):1859-1862. doi: 10.1016/j.amjcard.2019.02.051. Epub 2019 Mar 13.

PMID:
30922542
18.

Letter by Maron et al Regarding Article, "Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights From the Sarcomeric Human Cardiomyopathy Registry (SHaRe)".

Maron BJ, Rowin EJ, Maron MS.

Circulation. 2019 Mar 19;139(12):1557-1558. doi: 10.1161/CIRCULATIONAHA.118.038189. No abstract available.

PMID:
30883223
19.

Clinical Course and Significance of Hypertrophic Cardiomyopathy Without Left Ventricular Hypertrophy.

Maurizi N, Michels M, Rowin EJ, Semsarian C, Girolami F, Tomberli B, Cecchi F, Maron MS, Olivotto I, Maron BJ.

Circulation. 2019 Feb 5;139(6):830-833. doi: 10.1161/CIRCULATIONAHA.118.037264. No abstract available.

PMID:
30715937
20.

Benefit of Cardiac Resynchronization Therapy in End-Stage Nonobstructive Hypertrophic Cardiomyopathy.

Rowin EJ, Mohanty S, Madias C, Maron BJ, Maron MS.

JACC Clin Electrophysiol. 2019 Jan;5(1):131-133. doi: 10.1016/j.jacep.2018.08.018. No abstract available.

PMID:
30678779
21.

Case for Earlier Surgical Myectomy in Patients With Obstructive Hypertrophic Cardiomyopathy.

Maron MS, Spirito P, Maron BJ.

Circulation. 2018 Nov 6;138(19):2076-2078. doi: 10.1161/CIRCULATIONAHA.118.035484. No abstract available.

PMID:
30474424
22.

Clinical Course and Management of Hypertrophic Cardiomyopathy.

Maron BJ.

N Engl J Med. 2018 Nov 15;379(20):1977. doi: 10.1056/NEJMc1812159. No abstract available.

PMID:
30428294
23.

The Case for Takotsubo Cardiomyopathy (Syndrome) as a Variant of Acute Myocardial Infarction.

Sharkey SW, Maron BJ, Kloner RA.

Circulation. 2018 Aug 28;138(9):855-857. doi: 10.1161/CIRCULATIONAHA.118.035747. No abstract available.

PMID:
30354447
24.

Longevity in elite athletes: the first 4-min milers.

Maron BJ, Thompson PD.

Lancet. 2018 Sep 15;392(10151):913. doi: 10.1016/S0140-6736(18)31825-7. No abstract available.

PMID:
30238881
25.

Summary of Presentations and Discussions of Hypertrophic Cardiomyopathy at the 2018 Boston International Summit VI Including Consensus, Controversies, and Unmet Needs.

Maron BJ, Maron MS.

Am J Cardiol. 2018 Oct 1;122(7):1281-1286. doi: 10.1016/j.amjcard.2018.06.018. Epub 2018 Jul 4. No abstract available.

PMID:
30173818
26.

Reply: Atrial Fibrillation in Hypertrophic Cardiomyopathy.

Maron MS, Udelson JE, Rowin EJ, Maron BJ.

JACC Heart Fail. 2018 Sep;6(9):807-808. doi: 10.1016/j.jchf.2018.06.009. No abstract available.

27.

Survival After Takotsubo, Revisited.

Sharkey SW, Maron BJ.

J Am Coll Cardiol. 2018 Aug 21;72(8):883-884. doi: 10.1016/j.jacc.2018.06.022. No abstract available.

28.

Clinical Course and Management of Hypertrophic Cardiomyopathy.

Maron BJ.

N Engl J Med. 2018 Aug 16;379(7):655-668. doi: 10.1056/NEJMra1710575. Review. No abstract available.

PMID:
30110588
29.

Clinical Spectrum and Management Implications of Left Ventricular Outflow Obstruction With Mild Ventricular Septal Thickness in Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Chokshi A, Kannappan M, Arkun K, Wang W, Rastegar H, Maron MS.

Am J Cardiol. 2018 Oct 15;122(8):1409-1420. doi: 10.1016/j.amjcard.2018.06.055. Epub 2018 Jul 17.

PMID:
30107902
30.

Left ventricular apical aneurysm in hypertrophic cardiomyopathy as a risk factor for sudden death at any age.

Rowin EJ, Maron BJ, Chokshi A, Maron MS.

Pacing Clin Electrophysiol. 2018 Jun 12. doi: 10.1111/pace.13413. [Epub ahead of print] Review.

PMID:
29893504
31.

Response by Rowin et al to Letter Regarding Article, "Clinical Profile and Consequences of Atrial Fibrillation in Hypertrophic Cardiomyopathy".

Rowin EJ, Maron MS, Maron BJ.

Circulation. 2018 Jun 5;137(23):2541-2542. doi: 10.1161/CIRCULATIONAHA.118.034857. No abstract available.

PMID:
29866781
32.

Death and Cardiac Arrest in U.S. Triathlon Participants.

Harris KM, Creswell LL, Maron BJ.

Ann Intern Med. 2018 May 15;168(10):753. doi: 10.7326/L18-0023. No abstract available.

PMID:
29800442
33.

Global Burden of Hypertrophic Cardiomyopathy.

Maron BJ, Rowin EJ, Maron MS.

JACC Heart Fail. 2018 May;6(5):376-378. doi: 10.1016/j.jchf.2018.03.004. Review. No abstract available.

34.

Association Between Race and Clinical Profile of Patients Referred for Hypertrophic Cardiomyopathy.

Wells S, Rowin EJ, Bhatt V, Maron MS, Maron BJ.

Circulation. 2018 May 1;137(18):1973-1975. doi: 10.1161/CIRCULATIONAHA.117.032838. No abstract available.

PMID:
29712699
35.

Clinical Spectrum and Management of Heart Failure in Hypertrophic Cardiomyopathy.

Maron BJ, Rowin EJ, Udelson JE, Maron MS.

JACC Heart Fail. 2018 May;6(5):353-363. doi: 10.1016/j.jchf.2017.09.011. Epub 2018 Apr 11. Review.

36.

Clinical Course and Quality of Life in High-Risk Patients With Hypertrophic Cardiomyopathy and Implantable Cardioverter-Defibrillators.

Maron BJ, Casey SA, Olivotto I, Sherrid MV, Semsarian C, Autore C, Ahmed A, Boriani G, Francia P, Winters SL, Giudici M, Koulova A, Garberich R, Rowin EJ, Sears SF, Maron MS, Spirito P.

Circ Arrhythm Electrophysiol. 2018 Apr;11(4):e005820. doi: 10.1161/CIRCEP.117.005820.

PMID:
29625970
37.

Size as an Important Determinant of Chest Blow-induced Commotio Cordis.

Madias C, Maron BJ, Dau N, Estes NAM 3rd, Bir C, Link MS.

Med Sci Sports Exerc. 2018 Sep;50(9):1767-1771. doi: 10.1249/MSS.0000000000001630.

PMID:
29620687
38.

Effect of Spironolactone on Myocardial Fibrosis and Other Clinical Variables in Patients with Hypertrophic Cardiomyopathy.

Maron MS, Chan RH, Kapur NK, Jaffe IZ, McGraw AP, Kerur R, Maron BJ, Udelson JE.

Am J Med. 2018 Jul;131(7):837-841. doi: 10.1016/j.amjmed.2018.02.025. Epub 2018 Mar 28.

PMID:
29604289
39.

Surgical Approaches to Hypertrophic Obstructive Cardiomyopathy.

Solomon Z, Breton C, Rowin EJ, Maron BJ, Maron MS, Chen FY, Rastegar H.

Semin Thorac Cardiovasc Surg. 2018 Summer;30(2):125-128. doi: 10.1053/j.semtcvs.2018.02.034. Epub 2018 Mar 7. Review.

PMID:
29524602
40.

Impact of Advanced Therapies for Improving Survival to Heart Transplant in Patients with Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Abt P, Kiernan MS, Vest A, Costantino F, Maron MS, DeNofrio D.

Am J Cardiol. 2018 Apr 15;121(8):986-996. doi: 10.1016/j.amjcard.2017.12.044. Epub 2018 Jan 31.

PMID:
29496192
41.

Is It Fair to Screen Only Competitive Athletes for Sudden Death Risk, or Is It Time to Level the Playing Field?

Maron BJ, Estes NAM 3rd, Maron MS.

Am J Cardiol. 2018 Apr 15;121(8):1008-1010. doi: 10.1016/j.amjcard.2017.12.043. Epub 2018 Jan 31. No abstract available.

PMID:
29472006
42.

Clinical Profile of Nonresponders to Surgical Myectomy with Obstructive Hypertrophic Cardiomyopathy.

Wells S, Rowin EJ, Boll G, Rastegar H, Wang W, Maron MS, Maron BJ.

Am J Med. 2018 Jun;131(6):e235-e239. doi: 10.1016/j.amjmed.2017.12.031. Epub 2018 Jan 31.

PMID:
29353047
43.

Defibrillation threshold testing in hypertrophic cardiomyopathy: As SIMPLE as possible but not simpler.

Estes NAM 3rd, Maron BJ.

Heart Rhythm. 2018 Mar;15(3):393-394. doi: 10.1016/j.hrthm.2017.12.010. Epub 2017 Dec 8. No abstract available.

PMID:
29229517
44.

Harvey Feigenbaum, MD, and the Creation of Clinical Echocardiography: A Conversation With Barry J. Maron, MD.

Maron BJ.

Am J Cardiol. 2017 Dec 1;120(11):2085-2099. doi: 10.1016/j.amjcard.2017.08.033. Epub 2017 Oct 18. No abstract available.

PMID:
29156174
45.

Role of Exercise Testing in Hypertrophic Cardiomyopathy.

Rowin EJ, Maron BJ, Olivotto I, Maron MS.

JACC Cardiovasc Imaging. 2017 Nov;10(11):1374-1386. doi: 10.1016/j.jcmg.2017.07.016. Review.

46.

Interaction of Adverse Disease Related Pathways in Hypertrophic Cardiomyopathy.

Rowin EJ, Maron MS, Chan RH, Hausvater A, Wang W, Rastegar H, Maron BJ.

Am J Cardiol. 2017 Dec 15;120(12):2256-2264. doi: 10.1016/j.amjcard.2017.08.048. Epub 2017 Sep 20.

PMID:
29111210
47.

Death and Cardiac Arrest in U.S. Triathlon Participants, 1985 to 2016: A Case Series.

Harris KM, Creswell LL, Haas TS, Thomas T, Tung M, Isaacson E, Garberich RF, Maron BJ.

Ann Intern Med. 2017 Oct 17;167(8):529-535. doi: 10.7326/M17-0847. Epub 2017 Sep 19.

PMID:
28975231
48.

Alcohol septal ablation: in which patients and why?

Spirito P, Rossi J, Maron BJ.

Ann Cardiothorac Surg. 2017 Jul;6(4):369-375. doi: 10.21037/acs.2017.05.09.

49.

Results of surgical septal myectomy for obstructive hypertrophic cardiomyopathy: the Tufts experience.

Rastegar H, Boll G, Rowin EJ, Dolan N, Carroll C, Udelson JE, Wang W, Carpino P, Maron BJ, Maron MS, Chen FY.

Ann Cardiothorac Surg. 2017 Jul;6(4):353-363. doi: 10.21037/acs.2017.07.07.

50.

Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy.

Maron MS, Xin W, Sims KB, Butler R, Haas TS, Rowin EJ, Desnick RJ, Maron BJ.

Am J Med. 2018 Feb;131(2):200.e1-200.e8. doi: 10.1016/j.amjmed.2017.09.010. Epub 2017 Sep 21.

PMID:
28943383

Supplemental Content

Loading ...
Support Center